Typewriter Therapeutics

Typewriter Therapeutics is a biotechnology firm developing a novel class of genetic medicines designed to be safe, durable, and re-dosable for diseases like cancer, autoimmune disorders, and severe genetic conditions. The company, which was established in February 2022, emerged from stealth in September 2026 following a $56 million Series A financing round co-led by AN Venture Partners and RA Capital Management. With operations in Cambridge, Massachusetts, and Tokyo, Japan, the company aims to commercialize its proprietary gene insertion platform. The firm's core technology is a non-viral, all-RNA platform called Target-Primed Reverse Transcription (TPRT). This system is based on R2 retrotransposons, a natural gene-insertion mechanism. The therapy is delivered via lipid nanoparticles (LNPs) and consists of two RNA components: one mRNA that codes for the R2 protein and a second RNA that carries a full-length therapeutic gene. Inside the cell, this system inserts the therapeutic gene into a specific, safe-harbor site within the genome without making double-strand breaks, a key safety differentiator from other gene-editing tools. The delivery machinery then degrades, leaving the durable therapeutic gene in place. The company's scientific foundation is built upon decades of research by its academic co-founders, Professor Emeritus Haruhiko Fujiwara of the University of Tokyo and Professor Emeritus Tom Eickbush of the University of Rochester. The leadership team possesses significant experience in RNA and cell therapy. CEO Matthew Stanton previously served as Chief Scientific Officer at Generation Bio and as Vice President and Head of Chemistry at Moderna Therapeutics, where his team contributed to LNP technology for mRNA vaccines. Chief Scientific Officer Leanne Peiser brings extensive R&D experience, including leadership of CAR-T programs at Bristol Myers Squibb. Founder and VP of Discovery, Jun Zhou, studied the core R2 retrotransposon technology for his PhD and has over a decade of experience in the biopharmaceutical industry. Typewriter Therapeutics' business model focuses on developing its own pipeline of therapies. The initial strategy targets two high-value indications: genetic liver diseases and in vivo CAR-T therapy. The in vivo CAR-T approach seeks to engineer a patient's immune cells directly inside the body, potentially making cell therapy significantly more accessible and less complex than current ex vivo procedures. Following the Series A financing, the company is advancing its proof-of-concept work and plans to initiate its first non-human primate studies in late 2026. Keywords: gene insertion, Target-Primed Reverse Transcription, TPRT, R2 retrotransposon, genetic medicines, non-viral gene therapy, RNA therapeutics, in vivo CAR-T, cell therapy, lipid nanoparticles, LNP delivery, Haruhiko Fujiwara, Matthew Stanton, genetic liver diseases, autoimmune diseases, oncology, gene editing, site-specific integration, whole gene therapy, durable therapeutics, re-dosable medicine, AN Venture Partners, RA Capital Management, genomic medicine, biotechnology